Real-world evidence of mesenchymal stem cell therapy in knee osteoarthritis: a large prospective two-year case series

Julien Freitag, James Wickham, Kiran Shah, Abi Tenen

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
4 Downloads (Pure)

Abstract

Objective: To evaluate the long-term safety and efficacy of adipose-derived mesenchymal stem cell (ADMSC) therapy in the treatment of knee osteoarthritis (OA). Methods: 329 participants with knee OA underwent intra-articular ADMSC therapy. Participants were followed up for 24 months and were separated based on radiological OA grade. Results: Treatment was well tolerated with no related serious adverse events. All participant groups reported clinically and statistically significant pain improvement. Clinical outcome was not influenced by patients' age or BMI. Conclusion: ADMSC therapy is an effective, safe and long-lasting treatment option for knee OA with the potential to delay total joint replacement. In addition to the observed clinical benefits, ADMSC therapy promises to reduce the global economic burden of OA. Trial registration number: ACTRN1261700063833.

Original languageEnglish
Pages (from-to)355-373
Number of pages19
JournalRegenerative Medicine
Volume17
Issue number6
DOIs
Publication statusPublished - Jun 2022

Fingerprint

Dive into the research topics of 'Real-world evidence of mesenchymal stem cell therapy in knee osteoarthritis: a large prospective two-year case series'. Together they form a unique fingerprint.

Cite this